OpenAI trial live updates: Proceedings resume in landmark case

Elon Musk’s $134 billion lawsuit against Sam Altman, Greg Brockman, and Microsoft over OpenAI’s investments and nonprofit mission is now in trial in Oakland federal court, with a nine-person jury selected April 27. Microsoft CEO Satya Nadella testified for about three hours on May 10, Altman testified on May 12, and closing arguments are expected to begin May 14. The case highlights governance and competitive tensions around OpenAI and xAI, but near-term market impact is likely limited.

Analysis

MSFT is not facing a direct earnings event here; it is facing a narrative event that can leak into multiple valuation inputs at once. The key second-order risk is that a courtroom record forces more scrutiny on how deeply Microsoft is embedded in OpenAI’s economics, which could raise antitrust sensitivity just as AI capex is becoming a larger share of forward sentiment. That matters because the market is currently rewarding AI exposure as if the ecosystem were frictionless; any whiff of governance entanglement can compress the multiple even if near-term revenue is unchanged.

The bigger medium-term issue is option value dilution: if OpenAI’s strategic flexibility is constrained, Microsoft may have to shoulder more of the commercialization burden while also defending the partnership structure. That is a bad mix for margin perception because investors already debate whether AI monetization can keep pace with infrastructure spending over the next 6-18 months. In that frame, the lawsuit is less about a legal win/loss than about whether it slows the market’s willingness to underwrite a premium for MSFT’s AI adjacency.

A contrarian read is that the controversy may actually harden Microsoft’s bargaining position. If the market concludes OpenAI is the one with governance overhang and personnel instability, Microsoft’s stack becomes the perceived “safer” enterprise route to AI adoption, especially for CIO buyers who want continuity and compliance. The catalyst path therefore cuts both ways: near term, headlines and testimony can pressure the stock; over several quarters, any sign that the partnership remains intact could re-rate MSFT back upward because the market will view the litigation as noise relative to distribution scale.

Key Decisions for Investors

• Trim MSFT on litigation-driven strength over the next 1-3 weeks; use rallies to reduce exposure rather than chase, since the downside is multiple compression rather than fundamental earnings risk.
• For hedged exposure, pair long ORCL or AMZN against short MSFT for 1-2 months: both benefit from enterprise AI spend, while MSFT carries the cleaner legal/narrative overhang from this case.
• Buy MSFT downside protection via 1-2 month put spreads into the closing-argument window; risk/reward favors defined-risk hedges because catalyst timing is known and realized volatility can jump on any governance soundbite.
• If MSFT sells off 3-5% on headline risk without broader tech weakness, consider buying the dip for 6-12 month horizon: the structural enterprise demand story likely survives, and the lawsuit does not impair cash generation.
• Avoid initiating new aggressive longs in OpenAI-adjacent private-market proxies until after verdict/settlement visibility improves; the litigation raises the probability of a slower commercialization path, even if the market eventually treats it as a governance reset.